New insulin challenger: can GZR33 beat the standard for diabetes control?

NCT ID NCT07527078

Recruiting now Disease control Sponsor: Gan & Lee Pharmaceuticals. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 3 times

Summary

This Phase 3 trial will test a new once-daily insulin, GZR33, against the standard insulin degludec (Tresiba) in 350 adults with type 2 diabetes whose blood sugar is not well controlled by oral medications. The main goal is to see how well GZR33 lowers blood sugar over 26 weeks compared to the existing insulin. The study is not yet recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GZR33 injection (a new long-acting insulin)
What this could lead to: If successful, GZR33 could offer a new once-daily insulin option for people with type 2 diabetes, potentially improving blood sugar control.
What could go wrong: This is a Phase 3 trial, but it hasn't started recruiting yet. The new insulin may not prove superior or safer than the existing insulin degludec. As with any insulin, low blood sugar is a possible risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES (T2DM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES (T2DM)

Contacts and locations

Locations

Gan & Lee Pharmaceuticals
RECRUITING

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.